rs1553640314

Variant summary

Our verdict is Pathogenic. The variant received 22 ACMG points: 22P and 0B. PVS1PS1_ModeratePS3PP5_Very_Strong

The NM_001167617.3(MLH1):​c.3_4delGGinsTT​(p.MetAla1?) variant causes a start lost change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. It is difficult to determine the true allele frequency of this variant because it is of type MNV, and the frequency of such variant types in population databases may be underestimated and unreliable. Variant has been reported in ClinVar as Likely pathogenic (★★). ClinVar reports functional evidence for this variant: "SCV001178595: Based on an internal structural assessment, this alteration blocks the ATP binding site, and therefore may not affect protein expression (Ban C et al. Cell, 1999 Apr" and additional evidence is available in ClinVar. The gene MLH1 is included in the ClinGen Criteria Specification Registry.

Frequency

Genomes: not found (cov: 32)

Consequence

MLH1
NM_001167617.3 start_lost

Scores

Not classified

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:3U:1

Conservation

PhyloP100: 9.42

Publications

1 publications found
Variant links:
Genes affected
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
MLH1 Gene-Disease associations (from GenCC):
  • Lynch syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, G2P
  • Lynch syndrome 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp
  • Muir-Torre syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Genomics England PanelApp, Ambry Genetics, G2P, Orphanet
  • mismatch repair cancer syndrome 1
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics, G2P, ClinGen
  • Lynch syndrome 1
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • ovarian cancer
    Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
  • malignant pancreatic neoplasm
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • rhabdomyosarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • prostate cancer
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
  • breast cancer
    Inheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
  • hereditary breast carcinoma
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 22 ACMG points.

PVS1
Start lost variant, next in-frame start position is after 270 pathogenic variants. Next in-frame start position is after 144 codons. Genomic position: 37014478. Lost 0.218 part of the original CDS.
PS1
Another start lost variant in NM_001167617.3 (MLH1) was described as [Pathogenic] in ClinVar
PS3
PS3 evidence extracted from ClinVar submissions: SCV001178595: Based on an internal structural assessment, this alteration blocks the ATP binding site, and therefore may not affect protein expression (Ban C et al. Cell, 1999 Apr;97:85-97; Wu H et al. Acta Crystallogr F Struct Biol Commun, 2015 Aug;71:981-5).
PP5
Variant 3-37001039-GG-TT is Pathogenic according to our data. Variant chr3-37001039-GG-TT is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 525811.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_001167617.3. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
MLH1
NM_000249.4
MANE Select
c.292_293delGGinsTTp.Gly98Phe
missense
N/ANP_000240.1P40692-1
MLH1
NM_001167617.3
c.3_4delGGinsTTp.MetAla1?
start_lost
N/ANP_001161089.1P40692-3
MLH1
NM_001354620.2
c.3_4delGGinsTTp.MetAla1?
start_lost
N/ANP_001341549.1P40692-3

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
MLH1
ENST00000231790.8
TSL:1 MANE Select
c.292_293delGGinsTTp.Gly98Phe
missense
N/AENSP00000231790.3P40692-1
MLH1
ENST00000456676.7
TSL:1
c.292_293delGGinsTTp.Gly98Phe
missense
N/AENSP00000416687.3H0Y818
MLH1
ENST00000413740.2
TSL:1
c.292_293delGGinsTTp.Gly98Phe
missense
N/AENSP00000416476.2H0Y806

Frequencies

GnomAD3 genomes
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
Cov.:
32

ClinVar

ClinVar submissions
Significance:Pathogenic/Likely pathogenic
Revision:criteria provided, multiple submitters, no conflicts
View on ClinVar
Pathogenic
VUS
Benign
Condition
-
1
-
Carcinoma of colon (1)
1
-
-
Hereditary cancer-predisposing syndrome (1)
1
-
-
Hereditary nonpolyposis colorectal neoplasms (1)
1
-
-
not provided (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
PhyloP100
9.4

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1553640314; hg19: chr3-37042530; API
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.